JPRN-jRCT2033210029招募中1 期
Investigator-initiated, first-in-human trial of non-virally engineered GMR CAR T cells against CD116-positive acute myeloid leukemia and juvenile myelomonocytic leukemia. - GMR CAR-T
akazawa Yozo0 个研究点目标入组 21 人开始时间: 2021年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Subjects with CD116 positive myeloid malignancies who relapsed after HSCT or experienced induction failure.
- •2.Aged 18 or more in cohort 1, 1 or more and less than 18 in cohort 2 and 1 or more in cohort 3 at the time of study entry.
- •3.PS score (Age >= 16 years) >= 50 persent or Lansky score (Age < 15 years) >= 50 persent.
- •4.HSCT donors are available within 56 days after GMR CAR-T infusion.
- •5.Subjects capable of undergoing leukapheresis.
- •6.Adequate normal organ and tolerable disease control defined below.
- •a. WBC count <= 50,000 /micro-L
- •b. Absolute lymphocyte count >= 500/micro-L or CD3 positive T cells >= 150/micro-L.
- •c. Serum bilirubin <= 2.0 mg/dL.
- •d. AST <= 5-fold the upper limit of normal for age.
- •e. ALT <= 5-fold the upper limit of normal for age.
- •f. Serum creatinine <= 2.0 mg/dL.
- •g. SpO2 >= 95% (room air)
- •7.Left ventricular ejection fraction (EF) >= 50 persent, no pericardial effusion, and no abnormal electrocardiography findings requiring treatment.
- •8.Life expectancy >= 3 months.
- •9.Written informed consent can be obtained from patients and/or representatives.
排除标准
- •1.Subjects with prior or concurrent malignancies other than myeloid malignancies.
- •2.Subjects with poor disease control such as increasing leukemia cell counts in peripheral blood.
- •3.Subjects who received other CAR-T therapy within 24 weeks.
- •4.Acute promyelocytic leukemia (APL ; FAB M3).
- •5.Subjects with the active central nervous system and/or extramedullary disease.
- •6.Subjects with acute graft-versus-host disease (GVHD) (Grade >= 2) or extensive chronic GVHD.
- •Extensive chronic GVHD is either of either generalized skin involvement (>= 50 persent), localized skin involvement in the association with eye and/or oral involvement, abnormal liver histology (chronic progressive hepatitis, bridging necrosis, or cirrhosis), or other target organ involvement.
- •7.History of coronary heart disease, acute brain ischemia, or cerebral hemorrhage, or any sequelae of stroke such as paralysis.
- •8.Poorly controlled high blood pressure (systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg).
- •9.Subjects with uncontrollable and/or severe infections.
- •10.History of pulmonary fibrosis and/or interstitial pneumonia or radiological findings indicating the presence of pulmonary fibrosis and/or interstitial pneumonia.
- •11.Subjects with poorly controlled diarrhea and/or diabetes mellitus.
- •12.Subjects with poorly controlled severe heart diseases such as congestive heart failure and arrhythmia, acute brain ischemia, or cerebral hemorrhage. Heart failure is defined as class 3 or 4 cardiovascular disability according to New York Heart Association functional classification.
- •13.Subjects with severe organ complications such as renal failure, liver failure, or ileus.
- •14.Subjects who have psychological disorders affecting the participation in the trial.
- •15.HIV infection and/or HTLV-1 infection.
- •16.Positive for HBs antigen or HBc antigen and HBV-DNA.
- •17.Active hepatitis C infection.
- •18.Prior treatment with any investigational drugs within 30 days prior to enrollment.
- •19.Prior treatment with any investigational cell and gene therapies within 6 weeks prior to enrollment.
- •20.Subjects concurrently receiving the following treatments.
- •a. Corticosteroid (>= 6mg/m2/day equivalent prednisolone dose)
- •b. Donor lymphocyte infusion within 6 weeks prior to the enrollment
- •c. Treatment for GVHD (eg, calcineurin inhibitors, methotrexate, mycophenolate mofetil, TNF inhibitors, and IL-6 inhibitors)
- •d. Salvage chemotherapy must be completed by the time of second registration
- •21.Females who are pregnant and/or breastfeeding
- •22.Females of child-bearing potential who are not willing to practice highly effective methods of birth control from the time of consent through more than 12 months after GMR CAR-T cells and after confirmation of two consecutive negative test results of CAR-T in peripheral blood by qPCR. Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception from the time of consent to through more than 12 months after GMR CAR-T cells and after confirmation of two consecutive negative test results of CAR-T in peripheral blood by qPCR. As CAR-T cells can be transmitted through the sperm containing white blood cells, male subjects who underwent vasectomy must also practice sexual abstinence (refrain from heterosexual intercourse) or use contraception. Female subjects with no child-bearing potential (Age < 11 years old, amenorrhea for more than 24 months, hysterectomy,
研究者
相似试验
进行中（未招募）
1 期
The first-in-human trial of MDX-124 in patients with advanced cancerocally advanced, unresectable or metastatic solid malignanciesCancerISRCTN78740398Medannex Limited73
尚未招募
1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteersAcromegalyDRKS00032263niversität Heidelberg vertreten durch das Universitätsklinikum95
招募中
1 期
Safety, tolerability and pharmacokinetics of Investigator medication in healthy volunteersHealthy participantsJPRN-jRCT2071230087Sato Mika56
已完成
2 期
A clinical trial of a novel skin reconstruction treatment for GCMN.Congenital giant melanocytic nevusJPRN-jRCT2052210044Morimoto Naoki3
进行中（未招募）
1 期
First-in-human clinical trial using human cardiac stem cells obtained from a donor for Acute Myocardial Infarction treatment. Patients will receive either cells or placebo by intracoronary infusion to evaluate the safety and efficacy of this treatment.Acute Myocardial Infarction (AMI):First STEMI submitted to elective primary PCI with successful revascularization by PCI (TIMI = 3), but intermediate-high risk of HF development (infarct size by MRI>25%)EUCTR2013-001358-81-BECoretherapix S.L.U.55